Opal Wealth Advisors LLC Has $812,000 Position in Eli Lilly and Company (NYSE:LLY)

Opal Wealth Advisors LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 12.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 916 shares of the company’s stock after acquiring an additional 99 shares during the period. Opal Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $812,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Lynx Investment Advisory bought a new stake in Eli Lilly and Company during the second quarter worth about $32,000. LGT Financial Advisors LLC bought a new position in Eli Lilly and Company in the second quarter valued at about $36,000. Redmont Wealth Advisors LLC bought a new stake in Eli Lilly and Company during the 1st quarter worth about $40,000. Morton Brown Family Wealth LLC grew its position in shares of Eli Lilly and Company by 45.5% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after buying an additional 15 shares during the period. Finally, Cedar Mountain Advisors LLC lifted its holdings in Eli Lilly and Company by 53.3% in the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock valued at $41,000 after buying an additional 16 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $1,025.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Finally, Citigroup initiated coverage on shares of Eli Lilly and Company in a report on Friday, September 13th. They set a “buy” rating and a $1,060.00 price objective on the stock. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $979.29.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $913.85 on Wednesday. The company has a 50-day simple moving average of $916.37 and a two-hundred day simple moving average of $855.42. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53. The stock has a market capitalization of $868.53 billion, a price-to-earnings ratio of 134.59, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The company had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. Analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.